rs120074190
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PP3_ModeratePP5_Very_Strong
The NM_000218.3(KCNQ1):c.1766G>A(p.Gly589Asp) variant causes a missense change. The variant allele was found at a frequency of 0.0000223 in 1,613,604 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000218.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152192Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000478 AC: 12AN: 250966Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135748
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1461412Hom.: 0 Cov.: 32 AF XY: 0.0000206 AC XY: 15AN XY: 727038
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152192Hom.: 0 Cov.: 33 AF XY: 0.0000807 AC XY: 6AN XY: 74334
ClinVar
Submissions by phenotype
Long QT syndrome 1 Pathogenic:1
- -
Jervell and Lange-Nielsen syndrome 1 Pathogenic:1
- -
Jervell and Lange-Nielsen syndrome 1;C4551647:Long QT syndrome 1 Pathogenic:1
The c.1766G>A (p.Gly589Asp) variant in the exon 15 of KCNQ1 gene has been reported in heterozygous form in multiple unrelated individuals with long QT syndrome (LQTS) and in homozygous form in individuals with Jervell and Lange-Nielsen syndrome (PMID: 10483966, 11216980, 12477631, 12690509, 17329209, 19160088, 19716085, 20659946, 12402336, 23098067, 17467628, 17329207, 11799244, 22095730, 28619993). It is a founder mutation in the Finnish and Swedish populations (PMID: 11216980, 23098067). This variant is present at a frequency of 14/282342 in the gnomAD population database. Multiple lines of in silico algorithms predict the p.Gly589Asp change to be deleterious. Functional studies show that Gly589Asp affects the normal function of KCNQ1 potassium channel (PMID: 11216980, 15528464, 25344363, 22095730, 28785673, 28619993). In addition, multiple missense variants present in nearby residues (T587M, I588F, I588T, A590T, R591H, R591C, R591L, R594P, R594Q) have also been reported in affected individuals with LQTS. Therefore, this c.1766G>A (p.Gly589Asp) variant in the KCNQ1 gene is classified as pathogenic. -
not provided Pathogenic:1
The G589D pathogenic variant in the KCNQ1 gene has been reported multiple times in association with both LQTS and JLNS (Swan et al., 1999; Piippo et al., 2001; Saucerman et al., 2004; Marjamma et al., 2009; Kapplinger et al., 2009; Hintsa et al., 2010; Stattin et al., 2012). Several studies have reported G589D is a founder mutation in the Finnish population, with one study identifying the pathogenic G589D variant in 34 out of 114 Finnish individuals with autosomal dominant LQTS (Piippo et al., 2001; Marjamma et al., 2009). Furthermore, the G89D variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, and was not observed with any significant frequency in the Exome Aggregation Consortium (ExAC). G589D is a non-conservative amino acid substitution that is conserved across species. Multiple functional studies have demonstrated that G589D disrupts normal KCNQ1 channel function (Piippo et al., 2001; Saucerman et al., 2004; Heijman et al., 2012; Aromolaran et al., 2014). In addition, Kiviaho et al. (2015) reported that cardiomyocytes harboring G489D exhibited abnormal mechanical beating behavior with a prolonged phase of contracted state before relaxation. Finally, multiple pathogenic missense variants in nearby residues (T587M, A590T, R591H, R594P, R594Q) have been reported in the Human Gene Mutation Database in association with LQTS (Stenson et al., 2014), supporting the functional importance of this region of the protein.In summary, G589D in the KCNQ1 gene is interpreted as a pathogenic variant. -
Long QT syndrome Pathogenic:1
This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 589 of the KCNQ1 protein (p.Gly589Asp). This variant is present in population databases (rs120074190, gnomAD 0.05%). This missense change has been observed in individuals with Jervell and Lange-Nielsen syndrome and/or long QT syndrome (PMID: 10483966, 11216980, 19160088, 20659946, 22629021, 23098067, 28619993). It is commonly reported in individuals of Finland and Sweden ancestry (PMID: 10483966, 11216980, 19160088, 20659946, 22629021, 23098067, 28619993). ClinVar contains an entry for this variant (Variation ID: 3140). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNQ1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects KCNQ1 function (PMID: 22095730, 25344363). For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.G589D pathogenic mutation (also known as c.1766G>A), located in coding exon 15 of the KCNQ1 gene, results from a G to A substitution at nucleotide position 1766. The glycine at codon 589 is replaced by aspartic acid, an amino acid with similar properties. This alteration has been described in numerous patients with long QT syndrome and autosomal recessive Jervell and Lange-Nielsen syndrome, has been reported to segregate with disease in two large Finnish families, and is considered to be a founder mutation in the Finnish population (Piippo K et al. J Am Coll Cardiol. 2001;37(2):562-8). In several functional in vitro studies, this alteration adversely affected the voltage-gated potassium ion channel, resulting in decreased current amplitude, prolongation of the channel activation threshold, and trafficking defects (Piippo K et al. J Am Coll Cardiol. 2001;37(2):562-8; Marx SO et al. Science. 2002;295(5554):496-9). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Cardiac arrhythmia Pathogenic:1
This missense variant (also known as KCNQ1-Fin) replaces glycine with aspartic acid at codon 589 of the KCNQ1 protein. This variant is located in the C-terminal cytoplasmic coiled-coil domain that mediates tetramerization and formation of a functional channel. Computational prediction tools and conservation analyses are inconclusive regarding the impact of this variant on the protein function. Computational splicing tools suggest that this variant may not impact RNA splicing. Experimental functional studies have shown that this variant alters KCNQ1 channel function and hinders the channel complex transportation to the plasma membrane (PMID: 11216980, 22095730, 25344363, 28619993, 28785673). This variant is a well-known founder mutation in the Finnish population and occurs in 30% of Finnish individuals with long QT syndrome (PMID: 11216980, 27531917, 29622001, 29740400). Heterozygous carriers show a relatively benign clinical course, as only 10% of the carriers experiencing cardiac symptoms and their mean QTc was only moderately prolonged (PMID: 27531917). This variant has been reported in homozygosity in individuals affected with Jervell and Lange-Nielsen syndrome (PMID: 11216980, 29740400). This variant has been identified in 14/282342 chromosomes (14/24888 Finnish European chromosomes) in general populations by the Genome Aggregation Database (gnomAD). Based on available evidence, this variant is classified as Pathogenic. -
Congenital long QT syndrome Other:1
This variant has been reported as associated with Long QT syndrome in the following publications (PMID:10483966;PMID:11216980;PMID:12477631;PMID:12690509;PMID:17329209;PMID:19160088;PMID:19716085;PMID:20659946;PMID:12402336;PMID:17467628;PMID:17329207;PMID:11799244;PMID:22095730). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at